UBS Oconnor LLC
- SEC CIK
- 0001132716
- Latest filing
- Aug 14, 2026
HALO holding history
Halozyme Therapeutics, Inc. in every 13F filed by UBS Oconnor LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
HALO overviewAll 13F holders of HALOFull Q4 2025 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −24,683−100.0% | Sold out | Holders |
| Q3 2024 | 24,683 | $1.41M | <0.1% | −9,000−26.7% | Reduced | Holders |
| Q2 2024 | 33,683 | $1.76M | 0.1% | −26,000−43.6% | Reduced | Holders |
| Q1 2024 | 59,683 | $2.43M | 0.1% | +32,000+115.6% | Added | Holders |
| Q4 2023 | 27,683 | $1.02M | <0.1% | −40,860−59.6% | Reduced | Holders |
| Q3 2023 | 68,543 | $2.62M | <0.1% | −10,000−12.7% | Reduced | Holders |
| Q2 2023 | 78,543 | $2.83M | 0.1% | +8,623+12.3% | Added | Holders |
| Q1 2023 | 69,920 | $2.67M | 0.1% | +69,920 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −83,937−100.0% | Sold out | Holders |
| Q3 2022 | 83,937 | $3.32M | <0.1% | −4,000−4.5% | Reduced | Holders |
| Q2 2022 | 87,937 | $3.87M | <0.1% | +87,937 | New | Holders |